Inclusion Criteria:

          -  Diagnosis of EBV+ disorder

          -  Eastern Cooperative Oncology Group performance status <= 3 for participants aged >= 16
             years; Lansky score >= 20 for participants from 1 year to < 16 years

          -  Adequate organ function test results, unless organ dysfunction is considered to be due
             to the underlying LPD by the investigator

        Disease-Related inclusion criteria:

          -  For participants with PID LPD:

               -  Newly diagnosed or relapsed/refractory LPD histologically confirmed by
                  biopsy-proven EBV+ LPD or positive cerebrospinal fluid (CSF) cytology with or
                  without radiographically measurable intracranial disease with EBV detected in CSF

               -  Participant may have systemic only disease, CNS only disease, or both

               -  Definitive therapy (eg, allogeneic HCT, gene therapy) for the underlying PID is
                  planned

          -  For participants with AID LPD:

               -  Newly diagnosed or relapsed/refractory LPD histologically confirmed by
                  biopsy-proven EBV+ LPD or CNS disease must be measurable by MRI/CT or EBV must be
                  detected in CSF by lumbar puncture cytology

               -  Participant may have systemic only disease, CNS only disease, or both

               -  Participants who are human immunodeficiency virus positive (HIV+) must meet both
                  of the following criteria: Have an HIV viral load assessed by reverse
                  transcription-polymerase chain reaction (RT-PCR) below the lower limit of
                  detection and CD4 >= 50 cells/μL within 6 months prior to the first dose of
                  tabelecleucel.

          -  For participants with CNS PTLD:

               -  Newly diagnosed or relapsed/refractory EBV+ CNS PTLD histologically confirmed by
                  biopsy-proven EBV+ CNS PTLD or positive CSF cytology with or without
                  radiographically measurable intracranial disease with EBV detected in CSF

               -  Participant may have systemic and CNS disease or CNS only disease

          -  For participants with sarcoma, including LMS:

               -  Newly diagnosed or failed systemic first-line therapy for EBV+ sarcoma

               -  Biopsy-proven EBV+ sarcoma

               -  Measurable disease using diagnostic PET/CT and/or MRI following RECIST 1.1
                  criteria

          -  For participants with CAEBV:

               -  Newly diagnosed or previously treated CAEBV

               -  Detectable EBV viremia on at least 2 occasions at a minimum of 90 days apart

               -  At least 3 active clinical findings (per Kimura H, et al. Front Immunol.
                  2017;8:1867).

          -  For participants with EBV+ viremia with HLH:

               -  Newly diagnosed or previously treated EBV+ viremia with HLH

               -  A molecular diagnosis consistent with HLH-2004 trial (per Henter JI, et al.
                  Pediatr Blood Cancer. 2007;48:124-31) OR 5 or more of the clinical symptoms (per
                  Jordan MB, et al. Blood. 2011;118:4041-4052).

        Exclusion Criteria:

          -  Burkitt, T-cell (except in the setting of HLH), natural killer/T-cell lymphoma/LPD,
             Hodgkin, or transformed lymphoma

          -  Serious known active infections, defined as ongoing uncontrolled adenovirus infection
             or infections requiring active therapy, within 2 weeks prior to enrollment

          -  Suspected or confirmed Grade >= 2 acute graft-versus-host disease (GvHD) per the
             Center for International Blood and Marrow Transplant Research (CIBMTR) consensus
             grading system or extensive chronic GvHD per National Institutes of Health (NIH)
             consensus criteria at the time of the enrollment

          -  Need for vasopressor or ventilatory support

          -  Prior therapy (in order of increasing washout period) prior to enrollment as: within 4
             weeks or 5 half-lives (whichever is shorter) for any investigational product; and/or
             within <= 8 weeks for cellular therapies (EBV-CTLs, chimeric antigen receptor
             therapies directed at T cells or T-cell subsets, donor lymphocyte infusion, other
             CTLs); and/or therapies which could impact tabelecleucel function (anti-thymocyte
             globulin, alemtuzumab)

          -  Unwilling to use protocol specified contraceptive methods

          -  Women who are pregnant or breastfeeding

          -  For participants with involvement of CNS (CNS LPD or CNS PTLD):

               -  Participant actively receiving chemotherapy (systemic or intrathecal), or
                  radiotherapy treatment at the time of enrollment

               -  Daily steroids of > 0.5 mg/kg prednisone or glucocorticoid equivalent, ongoing
                  methotrexate, or extracorporeal photopheresis (protocol-specified dexamethasone
                  is permitted and concludes by the time of enrollment)

          -  For participants with PID LPD or AID LPD: history of prior allogeneic HCT or solid
             organ transplant

          -  For participants with EBV+ viremia: Participants with EBV+ viremia who do not meet
             inclusion criteria for CAEBV or HLH